Pharmaceuticals Europe

Europe Opioid Use Disorder Drugs Market Analysis, 2024–2034

Updated Reviewed by Chandani Patel

Europe Opioid Use Disorder Drugs Market Industry Trends and Forecast to 2034: Segmented by (Drug, Formulation, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

Europe · 2024–2034 · placeholder estimates

Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $959.5 Mn Placeholder estimate
Estimate 2025 $1.00 Bn 18.6% of the global market
Projected 2034 $1.50 Bn 49.9% Adds $500.8 Mn over 9 forecast years
CAGR 2025–2034 4.6% Faster than 22% of 186 Pharmaceuticals markets here
Key players 5 Companies profiled
  • Europe is 18.61% of the global market.
  • Among regions, the largest is North America at $2.99 Bn.
  • Fastest growing: Africa at 7.6% a year.
  • Europe ranks 3rd of 6 by size among regions.

Market size projection

Europe

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$500.8 Mn total, 2026–2034

Year-by-year market size, 2024–2034
Opioid Use Disorder Drugs Market market size by year, Europe
YearMarket sizeChange that yearSince 2025
2024 (estimate) $959.5 Mn — —
2025 (base) $1.00 Bn +$44.1 Mn —
2026 (forecast) $1.05 Bn +$46.2 Mn +4.6%
2027 (forecast) $1.10 Bn +$48.3 Mn +9.4%
2028 (forecast) $1.15 Bn +$50.5 Mn +14.4%
2029 (forecast) $1.20 Bn +$52.8 Mn +19.7%
2030 (forecast) $1.26 Bn +$55.3 Mn +25.2%
2031 (forecast) $1.31 Bn +$57.8 Mn +31%
2032 (forecast) $1.37 Bn +$60.5 Mn +37%
2033 (forecast) $1.44 Bn +$63.2 Mn +43.3%
2034 (forecast) $1.50 Bn +$66.2 Mn +49.9%

Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

Report snapshot

Europe Opioid Use Disorder Drugs Market Analysis at a glance
Market size, 2025$1.00 Bn placeholder estimate
Forecast, 2034$1.50 Bn placeholder estimate
Growth (CAGR), 2025–20344.6% placeholder estimate
Years2024 historical · 2025 base year · 2026–2034 forecast
SegmentsDrug, formulation and end user (see all)
Key playersIndivior, Alkermes, Orexo, Braeburn, Emergent BioSolutions (see all)
Regulator in EuropeEMASource: European Medicines Agency. Checked 14 Nov 2026.
Active clinical trials5 in EuropeSource: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Europe. Retrieved 12 Nov 2026.
FormatsPDF, PPTX, XLSX

Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.

The Europe Opioid Use Disorder Drugs Market Analysis Executive Summary

Opioid use disorder drugs such as buprenorphine, methadone and naltrexone reduce cravings and overdose risk.

Key segments of the opioid Use Disorder Drugs market include drug (Buprenorphine, Methadone and Naltrexone) and formulation (Sublingual, Extended-Release Injectable and Implants).

Bar chart: Europe Opioid Use Disorder Drugs market size, 2024–2034, placeholder estimates. $959.5 Mn in 2024, $1.00 Bn in 2025 and $1.50 Bn in 2034, 4.6% CAGR.
Europe Opioid Use Disorder Drugs market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.

Europe Opioid Use Disorder Drugs Market Dynamics

Market Growth Drivers

More people seeking help for mental health, less stigma, better screening and new treatments with faster effects are driving the opioid Use Disorder Drugs market. Governments and employers are investing more in mental health care.

Opportunity

Digital tools, new drug classes and care built into primary care and workplaces give the opioid Use Disorder Drugs market strong room to grow worldwide.

Market Restraints

Shortages of mental health professionals, limited insurance coverage, side effects and the need for long-term treatment hold back the opioid Use Disorder Drugs market.

Competitive Landscape for Opioid Use Disorder Drugs Market in Europe

The opioid Use Disorder Drugs market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.

Key Players

Healthcare Policies and Regulatory Landscape for Opioid Use Disorder Drugs Market in Europe

Opioid Use Disorder Drugs in Europe: rules, payment and research

In the EU, many new medicines are authorised once for every member state by the European Commission, after review by the European Medicines Agency (EMA).⁠[1] In the countries we cover here, medicines are approved by ANSM (France)⁠[2], BfArM (Germany)⁠[3], AIFA (Italy)⁠[4], Ministry of Health (Russia)⁠[5], AEMPS (Spain)⁠[6], MHRA (UK)⁠[7], CBG-MEB (Netherlands)⁠[8], FAMHP (Belgium)⁠[9], Swissmedic (Switzerland)⁠[10], Läkemedelsverket (Sweden)⁠[11], Danish Medicines Agency (Denmark)⁠[12], URPL (Poland)⁠[13] and TITCK (Turkey)⁠[14]. Each country runs its own health system and decides prices and reimbursement; since January 2025, EU countries also share joint clinical assessments of some new medicines.⁠[15] ClinicalTrials.gov lists 5 studies on Opioid Use Disorder Drugs that are recruiting, active or about to start in Europe.⁠[16]

[1] European Medicines Agency. Checked 14 Nov 2026.

[2] ANSM, French medicines agency. Checked 14 Nov 2026.

[3] Federal Institute for Drugs and Medical Devices (BfArM). Checked 14 Nov 2026.

[4] Italian Medicines Agency (AIFA). Checked 14 Nov 2026.

[5] Ministry of Health of the Russian Federation. Checked 14 Nov 2026.

[6] Spanish Agency of Medicines and Medical Devices (AEMPS). Checked 14 Nov 2026.

[7] Medicines and Healthcare products Regulatory Agency. Checked 14 Nov 2026.

[8] Medicines Evaluation Board (CBG-MEB). Checked 19 Nov 2026.

[9] Federal Agency for Medicines and Health Products (FAMHP). Checked 19 Nov 2026.

[10] Swissmedic. Checked 19 Nov 2026.

[11] Swedish Medical Products Agency (Läkemedelsverket). Checked 19 Nov 2026.

[12] Danish Medicines Agency. Checked 19 Nov 2026.

[13] Office for Registration of Medicinal Products, Medical Devices and Biocidal Products (URPL). Checked 19 Nov 2026.

[14] Turkish Medicines and Medical Devices Agency (TITCK). Checked 19 Nov 2026.

[15] European Commission, health technology assessment. Checked 14 Nov 2026.

[16] ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Europe. Retrieved 12 Nov 2026.

Policy changes and Reimbursement scenario

Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for opioid Use Disorder Drugs. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in Europe.

Beyond the market numbers

Research, trials and patients

What doctors and scientists are doing in Opioid Use Disorder Drugs right now, from free public sources.

Clinical trials

5 active trials in UK, Germany, France, Italy, Spain, Netherlands, Belgium, Switzerland, Sweden, Denmark, Poland, Turkey and Russia

Recruiting, about to start, or running now. Counted across the 13 countries we report on in Europe.

Top trial sponsors (worldwide)

  1. OpalGenix, Inc 2 active trials on ClinicalTrials.gov (opens in a new tab)

Source: ClinicalTrials.gov, Industry lead sponsors of active studies found with this market's trial search, worldwide. Retrieved 13 Nov 2026.

See every trial on ClinicalTrials.gov (opens in a new tab)

Patients

Suicide rate, per 100,000 people (WHO)
CountryValueYear
Belgium17.32023
Denmark9.92023
France16.52023
Germany13.12023
Italy7.22023
Netherlands10.82023
Poland14.82023
Russia21.82023
Spain8.62023
Sweden13.82023
Switzerland13.92023
Turkey3.72023
UK10.12023
Compare every country on the Public Health Dashboard

Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, WHO Global Health Observatory. Fetched 22 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.

Public data, with sources

Opioid Use Disorder Drugs in context

Free data on this topic

Quick answers

Frequently asked questions

How big is the Opioid Use Disorder Drugs market in Europe?
Placeholder estimate: about $1.00 Bn in 2025, rising to about $1.50 Bn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the Opioid Use Disorder Drugs market in Europe growing?
Placeholder estimate: about 4.6% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the Opioid Use Disorder Drugs market report cover?
The report splits the market by drug (Buprenorphine, Methadone, Naltrexone, Naloxone), formulation (Sublingual, Extended-Release Injectable, Implants, Nasal Spray) and end user (Hospitals, Specialty Clinics, Retail Pharmacies, Online Pharmacies).
Who are the key players in the Opioid Use Disorder Drugs market?
Key players include Indivior, Alkermes, Orexo, Braeburn and Emergent BioSolutions.
What is driving the Opioid Use Disorder Drugs market?
More people seeking help for mental health, less stigma, better screening and new treatments with faster effects are driving the opioid Use Disorder Drugs market. Governments and employers are investing more in mental health care.
Who regulates Opioid Use Disorder Drugs in Europe?
In the EU, many new medicines are authorised once for every member state by the European Commission, after review by the European Medicines Agency (EMA). Source: European Medicines Agency. Checked 14 Nov 2026.
How is healthcare paid for in Europe?
Each country runs its own health system and decides prices and reimbursement; since January 2025, EU countries also share joint clinical assessments of some new medicines. Source: European Commission, health technology assessment. Checked 14 Nov 2026.
How many clinical trials on Opioid Use Disorder Drugs are running in Europe?
5 studies are recruiting, active or about to start in Europe, counted across the 13 countries we report on there, according to ClinicalTrials.gov. Source: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Europe. Retrieved 12 Nov 2026.
How much research is published on Opioid Use Disorder Drugs?
PubMed lists 7,232 papers on Opioid Use Disorder Drugs added since January 2021, worldwide. Source: PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.
Back to Catalogue

Related Pharmaceuticals reports in Europe

See all

Related on mental health

See the topic